Eintrag weiter verarbeiten
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Gespeichert in:
Zeitschriftentitel: | Liver Cancer |
---|---|
Personen und Körperschaften: | , , , , , |
In: | Liver Cancer, 3, 2014, 3-4, S. 405-416 |
Medientyp: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
S. Karger AG
|
Schlagwörter: |
author_facet |
Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil |
---|---|
author |
Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil |
spellingShingle |
Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil Liver Cancer Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Oncology Hepatology |
author_sort |
choi, chihwan |
spelling |
Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil 2235-1795 1664-5553 S. Karger AG Oncology Hepatology http://dx.doi.org/10.1159/000343861 <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Liver Cancer |
doi_str_mv |
10.1159/000343861 |
facet_avail |
Online Free |
finc_class_facet |
Medizin |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE |
institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
imprint |
S. Karger AG, 2014 |
imprint_str_mv |
S. Karger AG, 2014 |
issn |
1664-5553 2235-1795 |
issn_str_mv |
1664-5553 2235-1795 |
language |
English |
mega_collection |
S. Karger AG (CrossRef) |
match_str |
choi2014multimodalitymanagementforbarcelonacliniclivercancerstagechepatocellularcarcinoma |
publishDateSort |
2014 |
publisher |
S. Karger AG |
recordtype |
ai |
record_format |
ai |
series |
Liver Cancer |
source_id |
49 |
title |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_unstemmed |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_full |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_fullStr |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_full_unstemmed |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_short |
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_sort |
multimodality management for barcelona clinic liver cancer stage c hepatocellular carcinoma |
topic |
Oncology Hepatology |
url |
http://dx.doi.org/10.1159/000343861 |
publishDate |
2014 |
physical |
405-416 |
description |
<jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> |
container_issue |
3-4 |
container_start_page |
405 |
container_title |
Liver Cancer |
container_volume |
3 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792334667126407168 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T14:31:54.008Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Multimodality+Management+for+Barcelona+Clinic+Liver+Cancer+Stage+C+Hepatocellular+Carcinoma&rft.date=2014-01-01&genre=article&issn=1664-5553&volume=3&issue=3-4&spage=405&epage=416&pages=405-416&jtitle=Liver+Cancer&atitle=Multimodality+Management+for+Barcelona+Clinic+Liver+Cancer+Stage+C+Hepatocellular+Carcinoma&aulast=Seong&aufirst=Jinsil&rft_id=info%3Adoi%2F10.1159%2F000343861&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792334667126407168 |
author | Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil |
author_facet | Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil, Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil |
author_sort | choi, chihwan |
container_issue | 3-4 |
container_start_page | 405 |
container_title | Liver Cancer |
container_volume | 3 |
description | <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> |
doi_str_mv | 10.1159/000343861 |
facet_avail | Online, Free |
finc_class_facet | Medizin |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE |
imprint | S. Karger AG, 2014 |
imprint_str_mv | S. Karger AG, 2014 |
institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
issn | 1664-5553, 2235-1795 |
issn_str_mv | 1664-5553, 2235-1795 |
language | English |
last_indexed | 2024-03-01T14:31:54.008Z |
match_str | choi2014multimodalitymanagementforbarcelonacliniclivercancerstagechepatocellularcarcinoma |
mega_collection | S. Karger AG (CrossRef) |
physical | 405-416 |
publishDate | 2014 |
publishDateSort | 2014 |
publisher | S. Karger AG |
record_format | ai |
recordtype | ai |
series | Liver Cancer |
source_id | 49 |
spelling | Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil 2235-1795 1664-5553 S. Karger AG Oncology Hepatology http://dx.doi.org/10.1159/000343861 <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Liver Cancer |
spellingShingle | Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil, Liver Cancer, Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma, Oncology, Hepatology |
title | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_full | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_fullStr | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_full_unstemmed | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_short | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
title_sort | multimodality management for barcelona clinic liver cancer stage c hepatocellular carcinoma |
title_unstemmed | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
topic | Oncology, Hepatology |
url | http://dx.doi.org/10.1159/000343861 |